Clinical Trial Update: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease [Phase 2, Phase 3]

View source ↗

Summary

Piromelatine 20 mg is being studied in participants with mild dementia due to Alzheimer's disease in Phase 2/3, and the trial is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Piromelatine

Snippet

Sponsor: Neurim Pharmaceuticals Ltd. | Conditions: Alzheimer's Disease | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING